Company Filing History:
Years Active: 2009-2015
Title: Innovations by Gonzalo González De Buitrago in Eye Disorder Treatments
Introduction
Gonzalo González De Buitrago is a prominent inventor based in Madrid, Spain, known for his significant contributions to the field of ocular health. With a total of 11 patents to his name, Gonzalo is at the forefront of developing innovative methods and compositions aimed at treating eye disorders, particularly those related to increased intraocular pressure.
Latest Patents
Among Gonzalo's latest patents are groundbreaking methods and compositions for the treatment of eye disorders characterized by increased intraocular pressure (IOP). These inventions focus on utilizing short interfering nucleic acid molecules (siNA), including short interfering RNA (siRNA), to decrease the expression of genes involved in the production or drainage of intraocular fluid. The compositions can be utilized in preparing medicaments for treating conditions such as glaucoma, inflammation, uveitis, and diabetic retinopathy. The methods proposed involve administering an effective amount of one or more siNAs to patients needing treatment.
Career Highlights
Gonzalo is currently associated with Sylentis S.A.U, a company dedicated to advancing research and development in the field of ophthalmology. His work aims to address critical challenges in eye care and provide innovative solutions that can substantially enhance patients' quality of life.
Collaborations
Throughout his career, Gonzalo has collaborated with several talented professionals in the field, including his coworkers Ana I Jiménez and Irene Gascón. Together, they contribute to the vibrancy of research and innovation at Sylentis S.A.U, fostering an environment where groundbreaking ideas can flourish.
Conclusion
Gonzalo González De Buitrago exemplifies the spirit of innovation through his contributions to the treatment of eye disorders. With his ongoing research and successful patents, he is making a lasting impact on the field of ophthalmology, paving the way for more effective therapies for patients suffering from eyes with elevated intraocular pressure.